N-terminal modified exendin-4
US9422349B2 · kind B2 · utility
6Cited by
7References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 16, 2008 |
| Grant date | Aug 23, 2016 |
| Priority date | — |
| Expiry date | Feb 21, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/605
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to an N-terminal amino acid-modified insulinotropic peptide having a high activity, and to a pharmaceutical composition comprising the same. The insulinotropic peptide derivatives according to the present invention exhibit therapeutic effects, which are not observed in native and other insulinotropic peptide analogs. Therefore, the insulinotropic peptide derivatives and the pharmaceutical composition comprising the same according to the present invention can be effectively provided for the treatment of the diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.